EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pioglitazone for the treatment of alcohol use disorder: A randomized controlled trial

Eric Dieperink iD, Katherine Anderson, Kathryn Dockter, Meredith Evenson, Paul Thuras, Peter Hauser

Addiction · 2026-10 · 121 (10) · 2661-2670

DOI: 10.1111/add.70508 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Addiction, online erschienen am 10.06.2026. Verfasst von Eric Dieperink und 5 weiteren Autor:innen. Beteiligte Einrichtung: Minneapolis Veterans Affairs Healthcare Systems, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Pioglitazone, PPAR-gamma Agonists, Alcoholism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Current medications for alcohol use disorders (AUD) are under‐used and of moderate benefit; new or improved treatments are much needed. Preclinical and small clinical studies indicate that pioglitazone, a thiazolidinedione agonist of the peroxisome proliferator‐activated receptor gamma, may reduce alcohol use. The primary purpose of this study was to evaluate, in a randomized trial, the effect of pioglitazone on alcohol use and craving in adults with AUD.

Design

A double‐blind, placebo‐controlled randomized trial.

Setting

Enrollment occurred in the United States at two Veterans Affairs Health Care Centers (VAHCS) from July 2019 to March 2024.

Participants

One hundred eighty‐five Veteran men and women older than 18 years with at least a moderate AUD and current alcohol use. Intervention and comparator Oral pioglitazone was given at dosages of 0 (placebo) ( n = 92), or 45 mg ( n = 93) over 14 weeks. All participants received Brief Behavioral Compliance Enhancement Treatment at each visit.

Measurements

The primary outcome measure was the number of heavy drinking days during week 14 as measured by the Timeline Follow Back (TLFB). Secondary measurements included the number of standard drinks consumed per week, the rate of no heavy drinking days over the last 8 weeks of the study, alcohol craving, anxiety, depression and post‐traumatic stress disorder symptoms. Exploratory outcome included change in alcohol use based on inflammation (C‐reactive protein) at baseline.

Findings

There was no difference between groups on the primary outcome (pioglitazone mean = 2.43, placebo mean = 2.01, difference = 0.43, 95% confidence interval = −0.25 to 1.10, P = 0.22). No differences were found between groups in secondary alcohol use measures or a measure of craving. Participants with elevated inflammation at baseline treated with pioglitazone had a greater decrease in heavy drinking days over time compared with placebo (z = 2.21, P = 0.03). Pioglitazone was safe and well tolerated.

Conclusions

Pioglitazone administered to people with alcohol use disorder at a dose of 45 mg per day appears to be safe although there is no evidence that it is efficacious in reducing alcohol use, alcohol craving or any psychiatric measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PioglitazonePPAR-gamma AgonistsAlcoholismHumansMaleDouble-Blind MethodFemaleMiddle AgedCravingTreatment OutcomeVeteransAdultUnited States

Stichwörter der Autor:innen

alcoholalcohol use disorderclinical trialinflammationpharmacologypioglitazone

Substanzen

PioglitazonePPAR-gamma Agonists

Autor:innen und Institutionen

  • Minneapolis Veterans Affairs Healthcare Systems, Minneapolis, MN, USA.
  • University of Minnesota-Medical School, Department of Psychiatry, Minneapolis, MN, USA.
  • Long Beach Veterans Affairs Healthcare Systems, Minneapolis, MN, USA.
  • Department of Psychiatry and Neuroscience, University of California-Riverside, Riverside, CA, USA.

ORCID-Profile: Eric Dieperink

Förderung

  • CSRD VA
  • U.S. Department of Veterans Affairs

Zitieren

APA

Dieperink, E., Anderson, K., Dockter, K., Evenson, M., Thuras, P., & Hauser, P. (2026). Pioglitazone for the treatment of alcohol use disorder: A randomized controlled trial. Addiction, 121(10), 2661-2670. https://doi.org/10.1111/add.70508

Vancouver

Dieperink E, Anderson K, Dockter K, Evenson M, Thuras P, Hauser P. Pioglitazone for the treatment of alcohol use disorder: A randomized controlled trial. Addiction. 2026;121(10):2661-2670. doi:10.1111/add.70508

BibTeX
@article{Dieperink2026,
  author = {Dieperink, Eric and Anderson, Katherine and Dockter, Kathryn and Evenson, Meredith and Thuras, Paul and Hauser, Peter},
  title = {Pioglitazone for the treatment of alcohol use disorder: A randomized controlled trial},
  journal = {Addiction},
  year = {2026},
  volume = {121},
  number = {10},
  pages = {2661--2670},
  doi = {10.1111/add.70508}
}
Kostenlos starten →